Evaluation of Minimal Residual Disease by Real-Time Quantitative PCR of Wilms' Tumor 1 Expression in Patients with Acute Myelogenous Leukemia after Allogeneic Stem Cell Transplantation: Correlation with Flow Cytometry and Chimerism

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 8, 2012, Pages 1235-1242

  Kwon, Mi ^a,b   Martínez Laperche, Carolina ^a,b   Infante, María ^b   Carretero, Fernando ^b   Balsalobre, Pascual ^a,b   Serrano, David ^a,b   Gayoso, Jorge ^a,b   Pérez Corral, Ana ^b   Anguita, Javier ^a,b   Díez Martín, Jose Luis ^a,b   Buño, Ismael ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Aberrant gene expression; Early detection; Molecular follow up; Relapse

Indexed keywords

BIOLOGICAL MARKER; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CHIMERA; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; PREDICTION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE; WHOLE BODY RADIATION;

ADULT; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; WILMS TUMOR; WT1 PROTEINS; YOUNG ADULT;

EID: 84864021078     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.01.012     Document Type: Article

References (21)

1. Bacher U., Zander A.R., Haferlach T., et al. Minimal residual disease diagnostics in myeloid malignancies in the post-transplant period. Bone Marrow Transplant 2008, 42:145-157.
2. Yang L., Han Y., Saurez Saiz F., et al. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007, 21:868-876.
3. Miwa H., Beran M., Saunders G.F. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992, 6:405-409.
4. Miyagi T., Ahuja H., Kubonishi I., et al. Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia 1993, 7:970-977.
5. Inoue K., Sugiyama H., Ogawa H., et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994, 84:3071-3079.
6. Inoue K., Ogawa H., Sonoda Y., et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997, 89:1405-1412.
7. Cilloni D., Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 2004, 112:79-84.
8. Ommen H.B., Nyvold C.G., Braendstrup K., et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008, 141:782-791.
9. Cilloni D., Renneville A., Hermitte F., et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009, 27:5195-5201.
10. Ogawa H., Tamaki H., Ikegame K., et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003, 101:1698-1704.
11. Dominietto A., Pozzi S., Miglino M., et al. Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood 2007, 109:5063-5064.
12. Candoni A., Tiribelli M., Toffoletti E., et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2009, 82:61-68.
13. Candoni A., Toffoletti E., Gallina R., et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant 2011, 25:308-316.
14. Lange T., Hubmann M., Burkhardt R., et al. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 2011, 25:498-505.
15. Cheson D.B., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the international Working Group for Diagnosis, Standardization of response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649.
16. Kreuzer K.A., Saborowski A., Lupberger J., et al. Fluorescent 50-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 2001, 114:313-318.
17. Beillard E., Pallisgaard N., Bi W., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): A Europe Against Cancer Program. Leukemia 2003, 17:2474-2486.
18. Jiménez-Velasco A., Barrios M., Román-Gómez J., et al. Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms. Leukemia 2005, 19:336-343.
19. San Miguel J.F., Vidriales M.B., López-Berges C., et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001, 98:1746-1751.
20. Buño I., Nava P., Simón A., et al. A comparison of fluorescent in situ hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell transplantation. Haematologica 2005, 90:1373-1379.
21. Pulsipher M.A., Bader P., Klingebiel T., et al. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant 2009, 15:62-71.